Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut

Tumor Biology

Volumn 37, Issue 3, 2016, Pages 2805-2810

  Bashir, Arif ^a   Miskeen, Abid Yousuf ^b   Hazari, Younis Mohammad ^a   Asrafuzzaman, Syed ^c   Fazili, Khalid Majid ^a  

^a UNIVERSITY OF KASHMIR   (India)

^b PUNJABI UNIVERSITY   (India)

^c North Orissa University ^*  (India)

Author keywords

Crohn s disease (CD); Fusobacterium nucleatum (F. nucleatum); Inflammatory bowel disease (IBD); T cell immunoglobulin and ITIM (TIGIT) domain; Ulcerative colitis (UC)

Indexed keywords

CELL ACTIVITY; COLORECTAL CANCER; DISEASE ASSOCIATION; FUSOBACTERIUM NUCLEATUM; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; T LYMPHOCYTE; ULCERATIVE COLITIS; COLORECTAL NEOPLASMS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PATHOGENICITY; TUMOR MICROENVIRONMENT;

COLORECTAL NEOPLASMS; FUSOBACTERIUM NUCLEATUM; HUMANS; INFLAMMATORY BOWEL DISEASES; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84952642815     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-015-4724-0     Document Type: Review

References (43)

1. Kostic AD et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–15.
2. Rubinstein MR et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206.
3. Tahara T et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74(5):1311–8.
4. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15(3):317–28.
5. Bashir A et al. Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. Eur J Cancer Prev. 2015;24(5):373–85.
6. Tjalsma H et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–82.
7. Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. BMJ. 2013;346:f432.
8. Yang T et al. Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med. 2013;19(12):714–25.
9. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–45.
10. Couturier-Maillard A et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest. 2013;123(2):700–11.
11. Jostins L et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24.
12. Gevers D et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–92.
13. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–99. doi:10.1053/j.gastro.2014.02.009.
14. Minot S et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res. 2011;21(10):1616–25. doi:10.1101/gr.122705.111.
15. Norman JM, Handley SA, Virgin HW. Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities. Gastroenterology. 2014;146(6):1459–69. doi:10.1053/j.gastro.2014.02.001.
16. Virgin HW. The virome in mammalian physiology and disease. Cell. 2014;157(1):142–50.
17. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–41.
18. Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol. 2013;29(1):85–91.
19. Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev. 2011;21(1):80–5.
20. Liu H, Redline RW, Han YW. Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J Immunol. 2007;179(4):2501–8.
21. Swidsinski A et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011;60(1):34–40.
22. Irrazabal T et al. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell. 2014;54(2):309–20.
23. McCoy AN et al. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013;8(1):e53653.
24. Dharmani P et al. Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun. 2011;79(7):2597–607.
25. Castellarin M et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306.
26. Kostic AD et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292–8.
27. Marchesi JR et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6(5):e20447. doi:10.1371/journal.pone.0020447.
28. Strauss J et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17(9):1971–8.
29. Kostic AD et al. Microbes and inflammation in colorectal cancer. Cancer Immunol Res. 2013;1(3):150–7.
30. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.
31. Mima K et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–61.
32. Moretta L et al. Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol. 1994;55:341–80.
33. Levin AM et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature. 2012;484(7395):529–33.
34. Koch J et al. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013;34(4):182–91. doi:10.1016/j.it.2013.01.003.
35. Seidel E, Glasner A, Mandelboim O. Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci. 2012;69(23):3911–20. doi:10.1007/s00018-012-1001-x.
36. Gur C et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–55. doi:10.1016/j.immuni.2015.01.010.
37. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
38. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60.
39. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48.
40. van den Boorn JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity. 2013;39(1):27–37.
41. Crespo J et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214–21. doi:10.1016/j.coi.2012.12.003.
42. Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51–60. doi:10.1016/j.it.2013.10.001.
43. Johnston RJ et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923–37. doi:10.1016/j.ccell.2014.10.018.